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This study assessed potential drugs interactions in intensive care patients at a university hospital in Ceará,
northeast Brazil. Of 102 patients studied, 72.5% were exposed to 311 potential drug-drug interactions; 64% of
them were females aged 60 years or more and hospital stay was at least 9 days. A statistically significant
association was found between number of drugs used and the occurrence of drug interactions. A total of 1,140
drugs were scheduled to be administered concomitantly; of these, 74% had potential for drug interactions. As
for the classification of these events, 48.2% had a pharmacokinetic profile; 55.4% were of slow onset; 54.7%
had moderate severity; and 60.6% were well-documented in the literature. The most common clinical action
taken was “to monitor signs and symptoms”. Nursing staff can perform 80% of preventive actions to avoid
undesirable effects of drug interactions. However, nurses need to have adequate knowledge about drug action
mechanisms and triggering factors associated to drug interactions.
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INTERACCIONES MEDICAMENTOSAS POTENCIALES EN PACIENTES DE UNA UNIDAD DE
TERAPIA INTENSIVA DE UN HOSPITAL UNIVERSITARIO
Este estudio investigó interacciones medicamentosas (IM) potenciales en una Unidad de Terapia Intensiva
(UTI) en un hospital universitario del Ceará. De los 102 pacientes del estudio, 72,5% presentaron 311 potenciales
IMs. De estos, 64% eran del sexo femenino, con edad mayor o igual a 60 años y tiempo de internación mayor
o igual a nueve días. Hubo una asociación estadísticamente significativa entre el número de medicamentos y la
ocurrencia de IM; 1.140 medicamentos fueron administrados durante el mismo horario, entre estos, 74%
presentaron potencial para IM. En lo que se refiere a la clasificación de las IMs, 48,2% presentaron un perfil
fármaco cinético, 55,4% inicio demorado, 54,7% moderada gravedad y 60,6% bien documentadas en la
literatura. El manejo clínico más frecuente fue “observar señales y síntomas”. Ochenta por ciento de las
intervenciones para evitar los efectos indeseables de las IMs pueden ser realizadas por el enfermero. Sin
embargo, para que estas ocurran, de hecho, es importante que el enfermero conozca los mecanismos
farmacológicos de las IMs, así como sus factores precipitantes.
DESCRIPTORES: unidades de terapia intensiva; interacciones de drogas
INTERAÇÕES MEDICAMENTOSAS POTENCIAIS EM PACIENTES DE UNIDADE DE TERAPIA
INTENSIVA DE UM HOSPITAL UNIVERSITÁRIO
Este estudo investigou interações medicamentosas (IM) potenciais em uma Unidade de Terapia Intensiva
(UTI) de um hospital universitário do Ceará. Dos 102 pacientes do estudo, 72,5% apresentaram 311 potenciais
IMs. Desses, 64% eram do sexo feminino, com idade maior ou igual a 60 anos e tempo de internação maior ou
igual a nove dias. Houve associação estatisticamente significativa entre o número de medicamentos e a
ocorrência de IM, e 1 140 medicamentos foram aprazados no mesmo horário. Desses, 74% apresentaram
potencial para IM. Quanto à classificação das IMs, 48,2% apresentaram perfil farmacocinético, 55,4% início
demorado, 54,7% moderada gravidade e 60,6% bem documentadas na literatura. O manejo clínico mais
freqüente foi “observar sinais e sintomas”. Oitenta por cento das intervenções para evitar os efeitos indesejáveis
das IMs podem ser realizadas pelo enfermeiro. No entanto, para que essas ocorram, de fato, é importante que
o enfermeiro conheça os mecanismos farmacológicos das IMs, bem como seus fatores precipitantes.
DESCRITORES: unidades de terapia intensiva; interações de medicamentos
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INTRODUCTION
Drug-drug interaction is an event that occurs
when the effects of a drug are modified when another
drug or food is taken concomitantly. This interaction
can cause reduced, null or increased drug effect(1).
Interactions can be classified, according to mechanisms
by which drugs interact with each other, as physical-
chemical, pharmacokinetic and pharmacodynamic.
Physical-chemical or pharmaceutical interaction occurs
when two or more drugs interact exclusively due to
physical-chemical mechanisms. Pharmacodynamic
interaction occurs when there is an added or antagonistic
effect of drugs. Pharmacokinetic interaction occurs when
a drug acts modifying absorption, distribution,
biotransformation, and elimination(2) of another drug.
Risk factors for drug interactions can be related
to patient, drug and medical prescription. Patient-related
factors include people that are more vulnerable to drug
interactions such as the elderly, patients undergoing
surgical procedures, those receiving intensive care
(ICU), and immunosuppressed patients. The main drug-
related risk factors are drug potency to cause effects of
enzyme induction and inhibition, and drug therapeutic
index, i.e. the ratio of the maximum tolerated dose to
the therapeutic dose. Risk factors related to medical
prescription include a large number of prescription drugs
needed for patients admitted to the hospital with complex
clinical conditions(3-4).
The occurrence of drug interactions
exponentially increases as the number of drugs
prescribed increases(5). It is estimated that drug
interactions occur in 3% to 5% of patients receiving a
small number of drugs, and increase to 10% to 20% in
patients receiving 10 to 20 drugs(6). As inpatients receive
on average seven different drugs a day, drug interaction
is evidently a significant concern, even more in ICU
settings where critical patients receive care and a large
range and quantity of drugs on a daily basis.
Although drug interactions have been widely
addressed in medical and pharmaceutical books and
journals, there have been scarce investigations in the
nursing area, especially bearing in mind that the nursing
team is responsible for the entire drug administration
process. Thus, to further explore this subject, a study
was conducted to assess potential drug interactions in
ICU patients in a hospital in the state of Ceará, northeast
Brazil. Studies on drug interactions focusing on nursing
clinical practice are important as a useful tool for decision
making during the drug administration process.
METHODS
Descriptive, exploratory, cross-sectional study
carried out in an ICU of a university hospital in Ceará.
All medical records of patients who were admitted to
the hospital ICU between June 2006 and June 2007
were reviewed. Patients who met the following criteria
were included: being over 18 years of age, and at
least 6-day stay in ICU. The latter inclusion criterion
was established as all drugs prescribed on Day 2 and
on Day 6 of ICU admission were recorded for analysis.
These days were selected because the majority of
drugs are prescribed on Day 1 of ICU admission, and
most therapeutic adjustments are made during this
first week of admission.
Of 362 patients admitted to ICU over one-
year period, 102 of them met the inclusion criteria.
The study was approved by the institutional Research
Ethics Committee of the study site (Process No.
050.06.02).
Data was collected using a questionnaire that
comprised two sections: section I included demographic
and patient identification information such as name
(initials), age, gender, and information about ICU
admission such as medical diagnoses on Day 2 and
Day 6, date of admission, and ICU stay. Section II
included information on drugs prescribed and
administration times.
The statistical analysis was performed using
SPSS® software v. 15.0. The chi-square test for
independence was used to test the association between
the variables age, gender, hospital stay, number of
drugs used, and medical diagnosis. A 5% significance
level was set. Drug interactions were analyzed using
Drug-Reax® System database from Micromedex®(7).
Potential drug interactions identified in the study were
classified by severity (minor, moderate, major, and
contraindicated), onset of action (fast, slow, and
indeterminate), documentation (excellent, good,
satisfactory, poor, and unknown), and pharmacokinetic
and pharmacodynamic profile.
In regard to severity, interactions were
classified as major, when they were life-threatening
and required immediate medical intervention;
moderate, when they aggravated the patient’s condition
and required drug therapy change; minor, when
patients experienced any change in their clinical
condition but did not require drug therapy change; and
contraindicated, when concomitant drug administration
was not recommended(7).
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As for onset of action, i.e. the expected time
between therapy start and the occurrence of adverse
events, drug interactions were classified as fast, when
adverse events due to drug-drug interaction occurred
within 24 hours; slow, when adverse events occurred
within more than 24 hours; and indeterminate, when
the time for onset of adverse events after concurrent
administration of drugs(7) was not documented in the
literature.
With respect to drug interaction documentation,
it was classified as excellent, when there were controlled
clinical studies evidencing drug-drug interactions; good,
when documentation about interaction was available but
no controlled clinical studies; satisfactory, when few
studies evidenced interaction but there were available
pharmacological considerations about drug interactions;
poor, when documentation was limited to case reports;
and unknown, when there was no documentation in the
literature evidencing drug interaction(7).
Drug interactions were further classified
according to the mechanism of interaction.
Pharmacokinetic interaction occurred when a drug was
likely to interfere with absorption, distribution,
metabolism, and elimination of another drug and
pharmacodynamic interaction occurred when drugs had
similar or antagonistic effects(7).
RESULTS
Of 102 patients studied, 66 (64.7%) were
males. Their age ranged between 18 and 96 years,
median 60 years (interquartile range: 41–70 years).
They stayed in the ICU at least five days and no more
than 163 days, median stay nine days (interquartile
range: 6–16 days).
As for the number of drugs prescribed on a
normal day, patients received one to 19 drugs on Day
2, and one to 17 drugs on Day 6, median nine drugs for
both days. The number of diagnoses ranged from one
to six on Day 2, and one to seven on Day 6, median
three diagnoses for both days. The most common
diagnostic classes were cardiovascular diseases (152;
24.9%), notably systemic arterial hypertension (37;
6%), and respiratory diseases, especially acute
respiratory failure (74; 12.1%).
In total, 1,845 drugs were identified in the
medical records examined, of which 924 on Day 2 and
921 on Day 6 of admission. They comprised 137 different
drug varieties.
The Anatomical Therapeutic Chemical (ATC)
Classification System(8) was used for the classification
of drugs. Drugs in the anatomical group “alimentary
tract and metabolism” were more frequently seen on
both days evaluated (474; 25.7%); followed by “anti-
infectives for systemic use” (344; 9.9%); “cardiovascular
system” (243; 13.1%) and “nervous system” (222;
12%). In each drug class, the most prescribed drugs
were: ranitidine (84; 17.7%); cefepime (64; 8.6%);
furosemide (2; 17.2%), and fentanyl (80; 36%).
The preferred administration route on Day 2
and Day 6 was intravenous (1,151 drugs administered;
62.3%); followed by oral administration (366; 19.8%);
inhalation (204; 11%); and subcutaneous (121; 6.5%).
Sublingual was seen in one case and intramuscular in
two cases.
As for administration times, of 1,845 drugs
studied, 1,140 (61.8%) were scheduled concomitantly,
and 844 (74%) of them showed potential for drug
interactions. Drugs were most often administered at 6
am, and up to nine drugs were administered at the same
time.
Of 102 patients studied, 74 showed 311
potential drug interactions, averaging three interactions
per patient (standard deviation [SD]: 3.7). Drug
interactions were most commonly seen in female
patients (47–64%), aged 60 or more (38–51.3%), and
in those who stayed in ICU for at least nine days (42–
56.7%) (Table 1).
An association was found between females and
drug interactions (p=0.004/95% CI: 0.095–0.74). As
for age and hospital stay, no association was found with
drug interactions.
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Table 1 – Association between the variables age, gender,
and hospital stay and drug interactions. Fortaleza, Brazil,
2007
*CI: confidence interval
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The variables medical diagnosis and number
of drugs used were analyzed on Day 2 and Day 6
separately, since they were different on these days.
It was found, however, that 71 patients (69.6%) had
less than three diagnoses on Day 2, 39 (55%) of whom
had drug interactions. On Day 6, most patients had
at least three medical diagnoses (77–75.5%), 40
(52%) of whom had drug interactions. Mean number
of medical diagnoses per patient showing drug
interactions was 2.8 on Day 2 and 3.3 on Day 6,
median three diagnoses for both days. However, no
association was seen between number of drug
interactions and number of diagnoses (p=0.99) (Table
2). The most common diagnostic classes on Day 2
and Day 6 were: cardiovascular (122; 26.6%),
respiratory (115; 25.1%), and gastrointestinal
diseases (45; 9.8%).
Table 2 – Association between the variables number
of drugs used and number of diagnoses on Day 2 and
Day 6 of ICU admission and drug interactions.
Fortaleza, Brazil, 2007
As for the number of drugs prescribed,
patients who potentially had drug interactions received
1,137 drugs, while those who did not potentially have
drug interactions received 437 drugs. Those who
received nine or more drugs had a higher rate of
drug interactions on both days studied. Yet, at a 5%
significance level, an association between number of
drugs prescribed on Day 6 and occurrence of drug
interactions (p<0.001) was found.
Of 311 potential drug interactions identified,
nervous system drugs accounted for 125 (40%).
Midazolam was the most common associated drug
(65–28%). Among the most interacting drugs,
midazolam and fentanyl were associated to 45
(14.5%) identified drug interactions.
In regard to the classification of potential
drug interactions identified in the study, 189 (60.6%)
had good documentation, 170 (54.7%) were of
moderate severity, and 173 (55.4%) of slow onset.
And the majority was classified as pharmacokinetic
interactions (150–48.2%).
Among actions that can be taken to minimize
or even prevent the effects of drug interactions,
80% can be performed by nursing staff: monitor
signs and symptoms (211; 47.9%); monitor the
therapeutic response (95; 20.6%); adjust
administration time (38; 8.2%); and avoid drug
combination (15; 3.3%).
DISCUSSION
As for sociodemographic characteristics, an
association was found between female gender and
drug interactions. This association may be explained
by the fact that most patients studied were women
and that, thus, they received a larger number of
drugs than men.
Potential drug interactions were most
commonly seen among those aged 60 or more (38;
51%). Similarly to gender, age is regarded as a risk
factor for drug interactions. Drug interactions are
more frequent in patients over 60 because they
suffer from chronic conditions requiring multidrug
therapy. The elderly are also more susceptible to
drug interactions due to deterioration of liver and
kidney function, as well as reduced drug metabolism
and elimination(9).
As for hospital stay, higher rates of drug
interactions (56.7%) were seen in patients who
stayed in ICU for longer than nine days.
The most common diagnostic classes with
potential for drug interactions were cardiovascular
diseases (122, 26.6%), especial ly arterial
hypertension (5.1%). Cardiovascular, renal and
endocrine diseases may be directly associated to
the occurrence of drug interactions due to factors
associated to patient characteristics and the drugs
used for their treatment(10).
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In regard to the number of drugs prescribed
on Day 2 and Day 6, a positive association was
found between the number of drugs prescribed and
potential drug interactions on Day 6 of ICU
admission (p<0.001). This association is
corroborated in many studies(3,11-12). However, in
addition to the number of drugs prescribed, many
of them were administered at the same time and
through the same route, which very likely may have
precipitated drug-drug interactions.
With respect to administration times, of
1,845 drugs studied, 1,140 (61.8%) were scheduled
to be administered concomitantly. Of them, 844 had
potential for drug interactions. Most drugs were
administered between noon and 4 p.m., but the most
frequent administration time was 6 a.m., when up
to nine drugs were administered at the same time.
This finding is corroborated by another study
investigating potential drug interactions in cancer
patients based on nursing administration schedule.
Higher drug administration was reported in the
evening (58.8%) and larger number of doses at 10
p.m. (39.6%)(13).
Few studies on drug interactions have
investigated drug administration time schedule as
a risk factor for drug interactions. Time schedule
fol lows the faci l i ty’s standard procedure,
disregarding the chance of drug-drug-interactions.
It should be mentioned that, in the facility studied,
nurses were responsible for establishing drug
administration time schedules. This is not the current
practice in hospital settings, however, being a task
assigned to either nursing assistants and/or ICU
clerical staff in many instances.
As for routes of drug administration, most
drugs were administrated intravenously (1,151;
62.3%) as expected, because it is the preferred
route in ICU patients, since most are severely ill
and require a fast route for immediate drug effects.
The second most common route was orally (19.8%).
Although most drugs were not administered orally,
this finding is remarkable because it makes us
question how drugs are being prepared and
administrated to patients, as most of them are
receiving oral drugs through a nasogastric tube.
It was found that 125 potential drug
interactions (40%) were associated to drugs acting
in the central nervous system. Notably, midazolam
was identified in 20.8% of these events, followed
by fentanyl (6.7%).
In regard to the most common drug
interactions, 14.5% were attr ibuted to the
association between midazolam and fentanyl. This
is the most severe interaction and has been well
documented in the literature. The association of
these drugs had addictive effects on the central
nervous system and can lead to respiratory
depression(7). Yet, the expected time lag for the
development of related adverse events has not
been clarif ied. But when these two drugs are
concomitantly administered, it is recommended to
carefully monitor the patient, preferably in an ICU
setting. In addition to ongoing patient monitoring,
dose reduction of one of these drugs, or both of
them, is recommended to minimize the effects of
this drug combination(7).
In conclusion, most potential drug
interactions identified in the present study had slow
onset (173; 55.4%), moderate severity (170;
54.7%) and were well-documented in the literature
(189; 60.6%). The majority were pharmacokinetic
(150; 48.2%), fol lowed by pharmacodynamic
interactions (138; 44.4 %), and 23 (7.4%) were
classif ied as unknown, i.e. the underlying
mechanism of interaction was not clear.
It is crucial that health providers are able
to identify and classify drug interactions, and know
how to clinically manage them, that is, how to
minimize or even prevent them. Of 311 drug
interactions identified, 461 clinical management
actions were taken, with up to three actions per
interaction. The main actions identified were:
monitor signs and symptoms (211; 47.9%); monitor
the therapeutic response (95; 20.6%); adjust dose
(85; 18.4%); adjust administration time (38; 8.2%);
avoid drug combination (15; 3.3%); replace drug
(4; 0.9%); and change administration route (3;
0.7%).
Although not al l  drug interactions are
preventable, dissemination of knowledge among
health providers about the main risk factors for drug
interactions and their mechanisms of interaction,
together with information about the most common
drug interactions that are clinically relevant, is key
to prevent these events. This knowledge will enable
health providers to choose therapeutic regimens and
drug administration times that are safer for patients,
providing better qual ity care and preventing
damages.
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